Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2019, Article ID 1939740, 7 pages
https://doi.org/10.1155/2019/1939740
Research Article

Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis

1Department of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland
2Department of Pediatric Radiology, Poznan University of Medical Sciences, Poznań, Poland
3Laboratory of Molecular and Cell Biology, Department of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland
4Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland

Correspondence should be addressed to A. Szczepankiewicz; moc.liamg@pezczsla

Received 12 June 2019; Revised 9 September 2019; Accepted 17 September 2019; Published 16 October 2019

Academic Editor: Vera L. Petricevich

Copyright © 2019 I. Wojsyk-Banaszak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. G. Liou, F. R. Adler, S. C. Fitzsimmons, B. C. Cahill, J. R. Hibbs, and B. C. Marshall, “Predictive 5-year survivorship model of cystic fibrosis,” American Journal of Epidemiology, vol. 153, no. 4, pp. 345–352, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. T. Britto, U. R. Kotagal, R. W. Hornung, H. D. Atherton, J. Tsevat, and R. W. Wilmott, “Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis,” Chest, vol. 121, no. 1, pp. 64–72, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. B. Sanders, R. C. Bittner, M. Rosenfeld, G. J. Redding, and C. H. Goss, “Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis,” Pediatric Pulmonology, vol. 46, no. 4, pp. 393–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. H. H. T. Robroeks, M. H. Roozeboom, P. A. De Jong et al., “Structural lung changes, lung function, and non-invasive inflammatory markers in cystic fibrosis,” Pediatric Allergy and Immunology, vol. 21, no. 3, pp. 493–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Svedberg, P. M. Gustafsson, P. D. Robinson, M. Rosberg, and A. Lindblad, “Variability of lung clearance index in clinically stable cystic fibrosis lung disease in school age children,” Journal of Cystic Fibrosis, vol. 17, no. 2, pp. 236–241, 2018. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Lukaszyk and J. Malyszko, “Copeptin: pathophysiology and potential clinical impact,” Advances in Medical Sciences, vol. 60, no. 2, pp. 335–341, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Nigro, B. Müller, N. G. Morgenthaler et al., “The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases,” Swiss Medical Weekly, vol. 141, article w13270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. N. G. Morgenthaler, B. Muller, J. Struck, A. Bergmann, H. Redl, and M. Christ-Crain, “Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock,” Shock, vol. 28, no. 2, pp. 219–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Latronico and C. A. Castioni, “Copeptin in critical illness,” Clinical Chemistry and Laboratory Medicine (CCLM), vol. 52, no. 10, pp. 1391–1393, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Yilman, A. K. Erenler, and A. Baydin, “Copeptin: a diagnostic factor for critical patients,” European Review for Medical and Pharmacological Sciences, vol. 19, no. 16, pp. 3030–3036, 2015. View at Google Scholar
  11. M. Potocki, T. Breidthardt, A. Mueller et al., “Copeptin and risk stratification in patients with acute dyspnea,” Critical Care, vol. 14, no. 6, p. R213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Du, G. Sang, C. M. Jiang, X. J. He, and Y. Han, “Relationship between plasma copeptin levels and complications of community-acquired pneumonia in preschool children,” Peptides, vol. 45, pp. 61–65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Christ-Crain, P. Schuetz, and B. Muller, “Biomarkers in the management of pneumonia,” Expert Review of Respiratory Medicine, vol. 2, no. 5, pp. 565–572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Kolditz, M. Halank, B. Schulte-Hubbert, S. Bergmann, S. Albrecht, and G. Höffken, “Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia,” Respiratory Medicine, vol. 106, no. 9, pp. 1320–1328, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Wrotek, T. Jackowska, and K. Pawlik, “Sodium and copeptin levels in children with community acquired pneumonia,” Adv Exp Med Biol, vol. 835, pp. 31–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Winther, J. Brynildsen, A. D. Høiseth et al., “Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study,” Respiratory Research, vol. 18, no. 1, p. 184, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Bilton, G. Canny, S. Conway et al., “Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials,” Journal of Cystic Fibrosis, vol. 10, Supplement 2, pp. S79–S81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. B. K. U. Sands, “Validation of Polish version of – Specific Quality of Life Questionnaire for Cystic Fibrosis (CFQ-R),” Pediatria Polska, vol. 84, no. 2, pp. 165–172, 2009. View at Google Scholar
  19. M. R. Miller, J. Hankinson, V. Brusasco et al., “Standardisation of spirometry,” European Respiratory Journal, vol. 26, no. 2, pp. 319–338, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Stollar, F. V. Adde, M. T. Cunha, C. Leone, and J. C. Rodrigues, “Shwachman-Kulczycki score still useful to monitor cystic fibrosis severity,” Clinics, vol. 66, no. 6, pp. 979–983, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Brasfield, G. Hicks, S. Soong, J. Peters, and R. Tiller, “Evaluation of scoring system of the chest radiograph in cystic fibrosis: a collaborative study,” American Journal of Roentgenology, vol. 134, no. 6, pp. 1195–1198, 1980. View at Publisher · View at Google Scholar · View at Scopus
  22. C. H. Goss and A. L. Quittner, “Patient-reported outcomes in cystic fibrosis,” Proceedings of the American Thoracic Society, vol. 4, no. 4, pp. 378–386, 2007. View at Google Scholar
  23. M. Katan, N. Morgenthaler, I. Widmer et al., “Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level,” Neuroendocrinology Letters, vol. 29, no. 3, pp. 341–346, 2008. View at Google Scholar
  24. M. Katan and M. Christ-Crain, “The stress hormone copeptin: a new prognostic biomarker in acute illness,” Swiss Medical Weekly, vol. 140, article w13101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Stolz, M. Christ-Crain, N. G. Morgenthaler et al., “Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD,” Chest, vol. 131, no. 4, pp. 1058–1067, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Boeck, J. B. Soriano, M. Brusse-Keizer et al., “Prognostic assessment in COPD without lung function: the B-AE-D indices,” European Respiratory Journal, vol. 47, no. 6, pp. 1635–1644, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. H. K. Jin, R. H. Yang, Y. F. Chen, R. M. Thornton, R. M. Jackson, and S. Oparil, “Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia,” Journal of Applied Physiology, vol. 66, no. 1, pp. 151–160, 1989. View at Publisher · View at Google Scholar
  28. N. Regamey, L. Tsartsali, T. N. Hilliard et al., “Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis,” Thorax, vol. 67, no. 2, pp. 164–170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. T. A. Laguna, B. D. Wagner, B. Starcher et al., “Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation,” Pediatric Pulmonology, vol. 47, no. 9, pp. 856–863, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. A. H. Shoki, N. Mayer-Hamblett, P. G. Wilcox, D. D. Sin, and B. S. Quon, “Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations,” Chest, vol. 144, no. 5, pp. 1659–1670, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. A. L. Quittner, A. C. Modi, C. Wainwright, K. Otto, J. Kirihara, and A. B. Montgomery, “Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection,” Chest, vol. 135, no. 6, pp. 1610–1618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. J. Dobbin, D. Bartlett, K. Melehan, R. R. Grunstein, and P. T. P. Bye, “The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 1, pp. 99–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. A. R. Horsley, J. C. Davies, R. D. Gray et al., “Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation,” Thorax, vol. 68, no. 6, pp. 532–539, 2013. View at Google Scholar
  34. J. Rothermel, A. Kulle, P. M. Holterhus, C. Toschke, N. Lass, and T. Reinehr, “Copeptin in obese children and adolescents: relationships to body mass index, cortisol and gender,” Clin Endocrinol (Oxf), vol. 85, no. 6, pp. 868–873, 2016. View at Publisher · View at Google Scholar · View at Scopus